通过PRDM16的代谢重编程驱动了急性骨髓性白血病中细胞氨基酸耐药性的驱动
Junji Ikeda1, Hiroyoshi Kunimoto2, Yusuke Saito3
1Department of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama.
Haematologica
|June 12, 2025
概括
在急性髓性白血病 (AML) 中,高PRDM16表达通过促进线粒体呼吸和MYC激活来驱动细胞因子抗性. 针对这种代谢途径可以克服AML患者的治疗失败.
科学领域:
- 血液学 血液学 血液学
- 分子生物学分子生物学
- 癌症新陈代谢 癌症新陈代谢
背景情况:
- 在急性髓性白血病 (AML) 中,高PRDM16表达与预后不佳和治疗失败相关.
- 驱动这种化学抵抗的潜在分子机制在很大程度上是未知的.
研究的目的:
- 阐明PRDM16在AML中对化疗产生耐药性的作用.
- 研究PRDM16调节的代谢途径,这些代谢途径有助于化学抵抗.
主要方法:
- 使用的小鼠MLL::AF9/sPrdm16AML模型用于体外和体外研究.
- 评估了对细胞氨酸 (AraC) 和环素的药物敏感性.
- 分析了基因表达,线粒体呼吸和代谢途径 (TCA循环,谷氨酸溶解).
- 研究了甲福明和tigecycline对AML细胞耐药性的影响.
主要成果:
- MLL::AF9/sPrdm16 AML 细胞对 AraC 呈现耐药性,但对 antracycline 没有耐药性.
- 增加PRDM16表达与高氧化酸化 (OxPHOS) 和线粒体呼吸增加有关.
- 抑制线粒体呼吸逆转了AraC的抵抗.
- PRDM16上调调节了MYC和Slc1a5,激活了TCA循环和谷氨酸溶解.
- 在高PRDM16.6的AML患者中,OxPHOS和MYC目标基因签名得到了丰富.
结论:
- 通过MYC-SLC1A5-Glutaminolysis轴激活线粒体呼吸和代谢重编程,PRDM16的过度表达促进了AML中的AraC耐药性.
- 准线粒体呼吸是一种潜在的治疗策略,可以克服PRDM16高AML的化学抵抗.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Introduction to Nuclear Reprogramming
1.9K
Nuclear reprogramming is the process of switching gene expression of one cell type to that of another cell type, usually from a differentiated cell state to an undifferentiated cell state. Differentiation occurs during processes such as development and morphogenesis, tissue regeneration, and malignancy. Cells can also be artificially induced to reprogram their gene expression by techniques such as nuclear transfer, induced pluripotency, and cell fusion. Such techniques have many applications in...
1.9K


